Loss of liver kinase B1 in human seminoma

Manish Kumar1, Subhransu S Sahoo1, M Fairuz B Jamaluddin1

  • 1School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.

Frontiers in Oncology
|March 27, 2023
PubMed

Insights

Loss of Liver kinase B1 (LKB1) expression is an early indicator in testicular germ cell cancer development. Targeting the mammalian target of rapamycin (mTOR) pathway with inhibitors shows promise for treating this malignancy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Testicular germ cell cancer originates from germ cells.
  • Liver kinase B1 (LKB1) is a tumor suppressor and mTOR pathway regulator.
  • LKB1 inactivation is common in human cancers.

Purpose of the Study:

  • Investigate LKB1's role in testicular germ cell cancer pathogenesis.
  • Assess mTOR inhibitors' efficacy in a seminoma model.

Main Methods:

  • Immunodetection of LKB1 in human seminoma samples.
  • Development of a 3D seminoma cell culture model (TCam-2).
  • Western blot and protein arrays to analyze mTOR pathway inhibition.

Main Results:

  • Reduced LKB1 expression observed in early lesions and seminoma.
  • TCam-2 3D model confirmed reduced LKB1 levels.
  • mTOR inhibitors decreased TCam-2 cell proliferation and survival.

Conclusions:

  • LKB1 downregulation is an early event in seminoma pathogenesis.
  • Targeting LKB1 downstream signaling offers a potential therapeutic strategy for testicular cancer.